New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
14:03 EDTADHDAlcobra submits INDA with FDA for Phase III trial
Alcobra announced the submission of an Investigational New Drug Application with the U.S. FDA to initiate a Phase III clinical trial with MG01CI. "With the submission of this IND, the company has achieved an additional major milestone in its development program of MG01CI for ADHD and other cognitive disorders. Given the positive results in our two previous Phase II studies in adults with ADHD we look forward to working closely with the FDA to meet the remaining requirements necessary to bring this therapy to the market," said Dr. Yaron Daniely, president & CEO of Alcobra.
News For ADHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
11:18 EDTADHDOptions with decreasing implied volatility
Subscribe for More Information
October 8, 2014
10:46 EDTADHDOptions with decreasing implied volatility
Subscribe for More Information
06:00 EDTADHDStocks with implied volatility below IV index mean; ADHD LULU
Stocks with implied volatility below IV index mean; Alcobra (ADHD) 123, lululemon (LULU) 35 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use